# Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

> **NCT02175355** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1039 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Low dose of Micardis®
- **DRUG:** Medium dose of Micardis®
- **DRUG:** High dose of Micardis®
- **DRUG:** Hydrochlorothiazide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02175355
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-10
- **Primary completion:** 2000-08
- **Final completion:** —
- **Target enrollment:** 1039 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175355, "Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02175355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*